Nuvation Bio Inc. (NUVB)
| Market Cap | 1.76B +37.9% |
| Revenue (ttm) | 169.90M +1,083.6% |
| Net Income | -149.83M |
| EPS | -0.44 |
| Shares Out | 351.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,957,048 |
| Open | 4.95 |
| Previous Close | 4.95 |
| Day's Range | 4.87 - 5.06 |
| 52-Week Range | 3.36 - 9.75 |
| Beta | 1.62 |
| Analysts | Strong Buy |
| Price Target | 13.00 (+160.0%) |
| Est. Earnings | Nov 2, 2026 |
About NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headqua... [Read more]
Financial Performance
In 2025, Nuvation Bio's revenue was $62.90 million, an increase of 698.96% compared to the previous year's $7.87 million. Losses were -$204.63 million, -63.97% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 160.00% from the latest price.
News
Nuvation Bio initiated with a Buy at Citi
Citi initiated coverage of Nuvation Bio (NUVB) with a Buy rating and $12 price target The firm views the company as an emerging oncology leader. The company’s Ibtrozi launch and…
Nuvation Bio announces FDA approval of sNDA for Ibtrozi
Nuvation Bio (NUVB) announced that the U.S. FDA has approved a supplemental New Drug Application for Ibtrozi, a ROS1 inhibitor approved for the treatment of locally advanced or metastatic ROS1-positiv...
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 months No changes to the safety sections of labeling with longer follow-up and no new safety signals identified Approv...
Nuvation Bio’s Ibtrozi shows durable efficacy in NSCLC studies
Nuvation Bio (NUVB) announced new subgroup analyses from the pivotal TRUST-I and TRUST-II studies evaluating Ibtrozi – taletrectinib – in both TKI- naive and TKI-pretreated patients with advanced ROS1...
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1 fusion-partner...
Nuvation Bio Transcript: Cantor Global Healthcare Conference
IBTROZI leads the ROS1 market with unmatched efficacy and safety, driving rapid adoption and strong revenue potential. Safusidenib shows promising results in glioma, targeting all subtypes with multiple trials underway. Robust cash reserves and a disciplined approach to business development support continued growth.
Nuvation Bio Transcript: Citigroup’s Biopharma Back to School Summit 2026
IBTROZI leads the ROS1 TKI market with strong efficacy and safety, while safusidenib shows unprecedented results in glioma, positioning it for significant market expansion. Educational efforts and improved testing are driving adoption, and the DDC platform promises future innovation.
Nuvation Bio to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hu...
Nuvation Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Nuvation Bio (NUVB) with an Overweight rating and no price target The firm views Nuvation as a “low-risk, high-reward” commercial-stage oncology story with “bes...
Nuvation Bio granted FDA Fast Track Designation for safusidenib in glioma
Nuvation Bio (NUVB) announced that the FDA has granted Fast Track Designation for safusidenib, the company’s investigational, oral, brain-penetrant selective inhibitor of mutant IDH1. The designation ...
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant glioma Pivota...
Nuvation Bio initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Nuvation Bio (NUVB) with an Overweight rating and $13 price target The company’s launch of Ibtrozi in non-small cell lung cancer is showing durable and growing…
Nuvation Bio price target raised to $14 from $12 at B. Riley
B. Riley raised the firm’s price target on Nuvation Bio (NUVB) to $14 from $12 and keeps a Buy rating on the shares following the Q2 report. Published first on…
Nuvation Bio price target raised to $20 from $19 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on Nuvation Bio (NUVB) to $20 from $19 and keeps an Outperform rating on the shares.
Nuvation Bio Slides: Corporate presentation
Nuvation Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Nuvation Bio Earnings Call Transcript: Q2 2026
IBTROZI net revenue grew 25% quarter-over-quarter, driven by strong first-line adoption and broad market leadership. Safusidenib's clinical program expanded to cover all IDH1 mutant glioma segments, and a 5x oversubscribed convertible debt financing strengthened the balance sheet.
Nuvation Bio Quarterly report: Q2 2026
Nuvation Bio has published its Q2 2026 quarterly earnings report on August 6, 2026.
Nuvation Bio Earnings release: Q2 2026
Nuvation Bio released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Nuvation Bio reports Q2 EPS (18c), consensus (12c)
Reports Q2 revenue $31.7M, consensus $27.47M. “IBTROZI is now the most prescribed ROS1 TKI in both first-line and overall new patient starts in 2026, based on IQVIA claims data from…
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI ® (taletrectinib) IBTROZI is the most prescribed ROS1 TKI in in both first-line ...
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
Analyses of long-term TRUST-I and TRUST-II data will examine consistency of efficacy across key patient subgroups NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncolo...
Nuvation Bio price target raised to $21 from $17 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Nuvation Bio (NUVB) to $21 from $17 and keeps a Buy rating on the shares after the company announced updated results from…
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
NEW YORK, July 22, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announ...
RBC looks for Nuvation shares to appreciate as safusidenib data builds
RBC Capital analyst Leonid Timashev notes Nuvation Bio (NUVB) has reported 40-month follow-up data for their glioma drug – safusidenib, which is a novel treatment for IDHmutant gliomas, a severe…
Nuvation Bio Slides: Corporate presentation
Nuvation Bio has posted slides in relation to its latest quarterly earnings report, which was published on July 20, 2026.